Ultra-small implanted neurostimulation device for the treatment of Obstructive Sleep Apnea

Informations projet

Nyxoah

N° de convention de subvention: 729044

DOI

10.3030/729044

Projet clôturé

Date de signature de la CE 21 Mai 2016

Date de début 1 Juin 2016

Date de fin 30 Septembre 2016

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

NYXOAH SA
Belgium

Periodic Reporting for period 1 - Nyxoah (Ultra-small implanted neurostimulation device for the treatment of Obstructive Sleep Apnea)

Période du rapport: 2016-06-01 au 2016-09-30

Résumé du contexte et des objectifs généraux du projet

Nyxoah project aims to introduce to the market a tiny HypoGlossal Nerve Stimulation (HGNS) system for the treatment of moderate to severe OSA patients who are not compliant with CPAP therapy. The key objectives of the project are to gather sufficient clinical evidence to commercialise the system as a CE certified medical device in Europe.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

During the Phase 1 Feasibility Assessment, Nyxoah accomplished a full analysis of the business potential of the Nyxoah’s GenioTM. Throughout the duration of the project, Nyxoah increased its knowledge of the medical device market, including regulations, medical device reimbursement standards, market size and competitors.
In the feasibility study, Nyxoah estimated that there are around 4.6 million OSA sufferers in Europe who need an alternative solution to treat this sleep disorder breathing. Nyxoah decided to primarily target already diagnosed patients who are non-compliant with CPAP (700K) or refuse CPAP (100K), sizing the potential market at 800K patients.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Nyxoah’s disruptive technology will promote health and wellbeing, and improve patient quality of life. Nyxoah proposes an innovative OSA treatment for patients and sleep specialists. Nyxoah’s GenioTM will offer a minimally invasive, effective and easy-to-use OSA alternative therapy to millions of OSA sufferers and thousands of sleep specialists.

Nyxoah’s GenioTM implant

Nyxoah’s GenioTM patch

Nyxoah’s GenioTM